Novartis blocks generic Galvus launch in India
This article was originally published in Scrip
Novartis in India has blocked generic firm Wockhardt from launching copies of Galvus (vildagliptin), its DPP-4 inhibitor for diabetes.
You may also be interested in...
Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.
Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.